Skip to main content
. 2018 Dec 29;11(1):19. doi: 10.3390/v11010019

Figure 1.

Figure 1

ZIKV neutralizing antibody titers detectable within days after ZIKV infection. (A) ZIKV-specific plasma IgM and IgG titers for patient ZK016 at 3 and 7 DPO and for ZK018 at 8 DPO. Titers were determined by ZIKV IgM antibody capture enzyme linked immunosorbent assay (MAC-ELISA) and modified IgG ELISA. The values are represented as ratios of the optical densities of patient plasma to healthy control plasma. For IgM, a ratio >3 = positive (dark gray), 2–3 = equivocal (light gray), >2 = negative (white) and for IgG, a ratio >1.5 = positive (dark gray), 1.2–1.5 = equivocal (light gray), >1.2 = negative (white). (B) Plasma endpoint IgG binding titers to ZIKV lysate as determined by ELISA. The dotted line indicates the starting plasma dilution of 1:100. (C) The Focus Reduction Neutralization Test (FRNT) titers of plasma from patients against ZIKV and DENV1-4. The values plotted are the plasma dilutions required for 50% neutralization of ZIKV foci, termed FRNT50. The FRNT assay for each sample was repeated in two or more independent experiments, and the mean values are plotted. The dotted line represents the starting plasma dilution of 1:30.